Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CR-001

Bispecific antibody · Immune activation, directed at PD-1 (PDCD1) and VEGF-A · developed by Crescent Biopharma

Phase 1/2 Most advanced trial
CBIO Developer
1 Registered trials

What is CR-001?

CR-001 is a tetravalent anti-PD-1/anti-VEGF-A bispecific antibody, built from a bivalent Fc-silenced IgG1 against VEGF-A with two PD-1-targeting single chain variable fragments fused to its C-terminus. It blocks PD-1 engagement by PD-L1 and PD-L2 to enhance T-cell tumor killing, and blocks VEGF-A binding to VEGFR1 and VEGFR2 to inhibit angiogenesis. It is studied in locally advanced or metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
PD-1 (PDCD1), VEGF-A, VEGFR1 (Flt1) (FLT1) (binding partner it blocks), VEGFR2 (KDR) (KDR) (binding partner it blocks)
Mechanism
Immune activation, directed at PD-1 (PDCD1) and VEGF-A
Pathways
VEGF-A/VEGFR signaling, tumor angiogenesis, PD-1/PD-L1 T-cell inhibition
Therapy area
Oncology
Developer
Crescent Biopharma, Inc. (CBIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07335497 Phase 1/2 Locally Advanced / Metastatic Solid Tumors Recruiting CBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced / Metastatic Solid Tumors

Other drugs acting on PDCD1 / VEGFA

More from Crescent Biopharma

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CBIO page.

Follow CBIO, the company behind CR-001

See CBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CBIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.